• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>GTx

GTx

GTx Inc GTXI

Last Price$0.59Day Change (%)1.24%
Open Price$0.58Day Change ($)0.01
Day Range0.58–0.5952-Week Range0.29–1.59

As of Wed 6/29/2016 11:17:00 AM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: AbbVie, Bavarian Nordic, ...

    Global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: AbbVie, Bavarian Nordic, GTx - Research and Markets

  2. How’s the Market Feeling These Days?

    GTx GTXI announced Thursday that the Data Safety Monitoring Board has given it the green light to proceed with Phase III trials for Acapodene. We're leaving our fair value estimate unchanged as we had anticipated a smooth interim review. In our opinion, Acapodene's potential exposure to generic ...

  3. America: The New Europe?

    GTx adds a European partner.

  4. When Flexibility Meets Opportunity in the European Commercial Real Estate Market

    We are raising GTx's fair value on recent positive Phase II trial results for Ostarine.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.